Clinical Trial Update: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) [Phase 1]

View source ↗

Summary

Electra Therapeutics is conducting a Phase 1 trial of ELA026 in relapsed/refractory T-cell and NK/T-cell malignancies, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma
• T-cell Malignancies

Drugs mentioned

• ELA026

Snippet

Sponsor: Electra Therapeutics Inc. | Conditions: T Cell Malignancies | Phase 1 | Status: RECRUITING